Role of a conserved lysine residue in the peripheral cannabinoid receptor (CB2): Evidence for subtype specificity

Molecular Pharmacology

Volumn 55, Issue 3, 1999, Pages 605-613

  Tao, Qing ^a   Mcallister, Sean D ^a   Andreassi, John ^a   Nowell, Katharine W ^a   Cabral, Guy A ^a   Hurst, Dow P ^b   Bachtel, Kevin ^b   Ekman, Marie C ^b   Reggio, Patricia H ^b   Abood, Mary E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b KENNESAW STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; CANNABINOID RECEPTOR; DRONABINOL; RECEPTOR SUBTYPE;

ARTICLE; CONFORMATIONAL TRANSITION; DRUG RECEPTOR BINDING; EMBRYO CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; KIDNEY CELL; PRIORITY JOURNAL; PROTEIN CONFORMATION; RECEPTOR AFFINITY; SITE DIRECTED MUTAGENESIS;

ALANINE; CELL LINE; CYCLOHEXANOLS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LIGANDS; LYSINE; MODELS, MOLECULAR; MORPHOLINES; MUTATION; NAPHTHALENES; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; SIGNAL TRANSDUCTION;

EID: 0032989004     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Abood ME and Tao Q (1995) Characterization of a delta opioid receptor in rat pheochromocytoma cells. J Pharmacol Exp Ther 274:1566-1573.
2. Ballesteros JA and Weinstein H (1995) Integrated methods for the construction of three dimensional models and computational probing of structure function relations in G protein-coupled receptors, in Methods in Neuroscience (Conn PM and Sealfon SM eds) pp 366-428, Academic Press, San Diego.
3. Bramblett RD, Panu AM, Ballesteros JA and Reggio PH (1995) Construction of a 3D model of the cannabinoid CB1 receptor: Determination of helix ends and helix orientation. Life Sci 56:1971-1982.
4. Cheng YC and Prusoff WH (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (IC50) on an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
5. Chin C, Abadji V, Lucas-Lenard J and Kendall D (1998) Ligand binding and modulation of cyclic AMP levels depends on the chemical nature of residue 192 of the human cannabinoid receptor 1. J Neurochem 70:366-373.
6. Compton DR, Johnson MR, Melvin LS and Martin BR (1992) Pharmacological profile of a series of bicyclic cannabinoid analogs: Classification as cannabimimetic agents. J Pharmacol Exp Ther 260:201-209.
7. Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K and Devane WA (1993) Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediate signal transduction. Proc Natl Acad Sci USA 90:7656-7660.
8. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, Lai Y, Ma AL and Mitchell RL (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48:443-450.
9. Howlett AC and Fleming RM (1984) Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol 26:532-538.
10. Huffman JW, Yu S, Showalter V, Abood ME, Wiley JL, Compton DR, Martin BR, Bramblett RD and Reggio PH (1996) Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J Med Chem 39:3875-3877.
11. Jeffrey GA (1997) An Introduction to Hydrogen Bonding in Biological Structures pp 22-26, Oxford University Press, New York.
12. Mackie K and Hille B (1992) Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci. USA 89:3825-3829.
13. Mackie K, Lai Y, Westenbroek R and Mitchell R (1995) Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with the rat brain cannabinoid receptor. J Neurosci. 15: 6552-6561.
14. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC and Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564.
15. Munro S, Thomas KL and Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for Cannabinoids. Nature 365:61-65.
16. Nowell KW, Pettit DAD, Cabral WA, H. W. Zimmerman J, Abood ME and Cabral GA (1998) High level expression of the human CB2 cannabinoid receptor using a baculovirus system. Biochem Pharmacol 55:1893-1905.
17. Papworth C, Bauer J, Braman J and Wright D (1996) Site-directed mutagenesis in one day with >80% efficiency. Strategies 9:3-4.
18. Pearlman D, Case D, Caldwell J, Seibel G, Singh U, Weiner P and Kollman P (1991) Amber 4.0. University of California, San Francisco.
19. Reggio PH, Basu-Dutt S, Hurst DP, Patel MJ, Seltzman HH and Thomas BF (1997) What is the bioactive conformation of amino-alkylindoles at the CB1 receptor? Insights gained from E and Z napthylidene indenes, in Symposium on the Cannabinoids, International Cannabinoid Research Society p 47, Stone Mountain, GA.
20. Rosenthal HE (1967) A graphic method for the determination and presentation of binding parameters in a complex system. Anal Biochem 20:525-537.
21. Scatchard G (1951) The attractions of proteins for small molecules and ions. Ann NY Acad Sci 51:670-672.
22. Shire D, Calandra B, Delpech M, Dumont X, Kaghad M, Fur GL, Caput D and Ferrara P (1996) Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A. J Biol Chem 271:6941-6946.
23. Showalter VM, Compton DR, Martin BR and Abood ME (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278:989-999.
24. Slipetz DM, O'Neill GP, Favreau L, Dufresne C, Gallant M, Gareau Y, Guay D, Labelle M and Metters KM (1995) Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol Pharmacol 48:352-361.
25. Song Z-H and Bonner TI (1996) A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol Pharmacol 49:891-896.
26. 2, disrupts G-protein coupling. J Pharmacol Exp Ther 285:651-658.
27. Tius M, Hill W, Zou X, Busch-Petersen J, Kawakami J, Fernandez-Garcia M, Drake D, Abadji V and Makriyannis A (1995) Classical/non-classical cannabinoid hybrids; stereochemical requirements for the southern hydroxyalkyl chain. Life Sci 66:2007-2012.
28. Unger V, Hargrave P, Baldwin J and Schertler G (1997) Arrangement of rhodopsin transmembrane alpha-helices. Nature 389:203-206.
29. Xie XQ, Melvin LS and Makryiannis A (1996) The comformational properties of the highly selective cannabinoid receptor ligand CP-55,940. J Biol Chem 271:10640-10647.